184 related articles for article (PubMed ID: 38343381)
1. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.
Espinosa De Ycaza AE; Brito JP; McCoy RG; Shao H; Singh Ospina N
Thyroid; 2024 Apr; 34(4):403-418. PubMed ID: 38343381
[No Abstract] [Full Text] [Related]
2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
3. Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.
Makunts T; Joulfayan H; Abagyan R
JMIRx Med; 2024 May; 5():e55976. PubMed ID: 38738836
[TBL] [Abstract][Full Text] [Related]
4. Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
Mizubuti GB; Ho AM; Silva LMD; Phelan R
Curr Opin Anaesthesiol; 2024 Jun; 37(3):323-333. PubMed ID: 38390914
[TBL] [Abstract][Full Text] [Related]
5. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
Akbari A; Hadizadeh S; Heidary L
J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System.
Makunts T; Joulfayan H; Abagyan R
medRxiv; 2023 Nov; ():. PubMed ID: 38045343
[TBL] [Abstract][Full Text] [Related]
8. A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
Hu EH; Tsai ML; Lin Y; Chou TS; Chen TH
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541083
[TBL] [Abstract][Full Text] [Related]
9. A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
Goldenberg RM
Diabetes Obes Metab; 2024 Jul; 26(7):2997-2999. PubMed ID: 38576082
[No Abstract] [Full Text] [Related]
10. Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.
Hu JC; Shao SC; Tsai DH; Chuang AT; Liu KH; Lai EC
JAMA Netw Open; 2024 Mar; 7(3):e240946. PubMed ID: 38436955
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists: A review of glycemic benefits and beyond.
Clark L
JAAPA; 2024 Apr; 37(4):1-4. PubMed ID: 38531038
[TBL] [Abstract][Full Text] [Related]
12. From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer.
Alhajahjeh A; Al-Faouri R; Bahmad HF; Bader T; Dobbs RW; Abdulelah AA; Abou-Kheir W; Davicioni E; Lee DI; Shahait M
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672620
[TBL] [Abstract][Full Text] [Related]
13. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.
Hu W; Song R; Cheng R; Liu C; Guo R; Tang W; Zhang J; Zhao Q; Li X; Liu J
Front Endocrinol (Lausanne); 2022; 13():927859. PubMed ID: 35898463
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship.
Hui BTK; Yeong JL; Peto T; Willoughby CE
Peptides; 2024 May; 178():171240. PubMed ID: 38705472
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M; Frere L; Tunnicliffe DJ; Nagler EV; Manja V; Åsvold BO; Jha V; Vermandere M; Gariani K; Zhao Q; Ren Y; Cartwright EJ; Gee P; Wickes A; Ferns L; Wright R; Li L; Hao Q; Mustafa RA
BMJ; 2021 May; 373():n1091. PubMed ID: 33975892
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
18. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.
Mali G; Ahuja V; Dubey K
J Clin Pharm Ther; 2021 Feb; 46(1):99-105. PubMed ID: 32926446
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
